For richer charts and full features, open SpikePanel on desktop.

Biotech catalyst calendar

Track clinical readouts, regulatory milestones and market repricing by date.

Updated 11/11, 12:01 PM · US Eastern time · Selected public disclosures. This calendar is not exhaustive.

FDA official calendar

November 2026

Linked stocks only

14 events · 14 stocks

MonTueWedThuFriSatSun

Wed, November 11

1 events

Prices and changes reflect the labeled regular, pre-market, after-hours or closed session, not the event day. First close is the change from the baseline to the first post-disclosure close, shown only with verified timing and history.

Month / quarter windows

Not assigned to a specific day

Upcoming catalysts

PDUFA dates are review targets. They do not guarantee approval or a decision on that day. Selected public disclosures. This calendar is not exhaustive.

Updated 11/11, 12:01 PM · US Eastern time

UpcomingPhase 3 readout

SGT-610

Indication not verified; see the original disclosure.

Company-guided readout

November 2026

Evidence source

Company disclosure

$SLGL

Quote unavailable

Price trend

Loading price history…

Company & funding

Market cap snapshot: $206.3M; 11/05
Cash & short-term investments: $47.9M
Total debt: $770K

Statement period end: 2026-06-30 · FMP financial data. Filed: 2026-08-20.

SEC filings

Disclosure & review details

Readout guidance

Timing is explicit company guidance and may change. Month/quarter windows are not assigned an invented day; study completion is not a results announcement.

Original source

Evidence & updates

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept.